A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Esketamine (Primary) ; Duloxetine; Escitalopram; Sertraline; Venlafaxine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms TRANSFORM-2
- Sponsors Janssen Research & Development
- 27 Sep 2017 This trial has been completed in Spain.
- 21 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Apr 2017 Planned primary completion date changed from 24 Mar 2017 to 6 Jun 2017.